Foundation for innovation
in Cardiometabolism and Nutrition

IHU-ICAN

Communication

TRaining

clinical TEams

Cardiometabolism

INnovative care Pathways

Reference Centers

Research Teams

research

research focus Area

Our Support

clinical Investigation

scientific Plateforms

Parterships

Why Support ICAN?

How to support ICAN?

projects to Support

Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab

Digestive and Liver Disease

Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab

Posted on 

Stay in touch

Get all the latest news from the ICAN Foundation

This field is for validation purposes and should be left unchanged.

OUr founders

ISO 9001 Certified

OUr Institutionnal Supporters

Our network